Vol. IV · No. 19
Thursday, May 14, 2026
Issue: Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence · Editorial desk

From the editorial desk

Evidence analysis, trial updates, and longevity science — reviewed before publication.

8 articles published · 5 categories · Updated continuously
§ Categories · 5
01
Intervention Profiles
3 articles
02
Clinical Trials
1 article
03
Evidence Analysis
1 article
04
Longevity Science
1 article
05
Editorial
2 articles
§ All articles · newest first
Intervention Profiles
Rapamycin for longevity: what the clinical evidence actually shows in 2026
A structured synthesis of every published human trial and major animal study — evidence strength rated honestly, with what is known, what is unknown, and what trials are ongoing.
May 13, 2026  ·  14 min read
Intervention Profiles
GLP-1 agonists beyond weight loss: the cardiovascular and longevity evidence
Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.
May 13, 2026  ·  12 min read
Intervention Profiles
SGLT2 inhibitors and aging: what the evidence actually shows
Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated. Here is the evidence.
May 13, 2026  ·  10 min read
Clinical Trials
The TAME trial explained: what metformin's biggest longevity test will actually tell us
TAME is the most significant longevity trial running. What the trial design means, what a positive result would and would not prove, and what interim signals look like.
May 10, 2026  ·  11 min read
Evidence Analysis
NMN vs NR: comparing the evidence for the two main NAD+ precursors
A direct head-to-head comparison of every published human trial for NMN and NR — evidence rated honestly, and what the first head-to-head trial will tell us.
May 8, 2026  ·  9 min read
Longevity Science
The hallmarks of aging explained: a clinical reference
The twelve hallmarks of aging are the biological framework underlying every intervention in the longevity pharmacopeia. What each hallmark is, why it matters clinically, and which interventions target it.
May 7, 2026  ·  16 min read
Editorial
Why Geroevidence exists
A statement of purpose — what we are building, who it is for, and what we will never claim to be.
May 6, 2026  ·  5 min read
Editorial
How Geroevidence came to be
The origin of a clinical evidence platform — built not by a physician, but by someone who works inside the healthcare system and grew tired of watching good science reach clinicians poorly.
May 5, 2026  ·  6 min read